Michael Burkes Brophy Sells 496 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 496 shares of Natera stock in a transaction that occurred on Wednesday, October 23rd. The shares were sold at an average price of $119.09, for a total transaction of $59,068.64. Following the transaction, the chief financial officer now directly owns 74,314 shares in the company, valued at approximately $8,850,054.26. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Michael Burkes Brophy also recently made the following trade(s):

• On Monday, October 21st, Michael Burkes Brophy sold 608 shares of Natera stock. The shares were sold at an average price of $120.76, for a total transaction of $73,422.08.
• On Wednesday, July 31st, Michael Burkes Brophy sold 1,866 shares of Natera stock. The shares were sold at an average price of $99.65, for a total transaction of $185,946.90.
• On Monday, July 29th, Michael Burkes Brophy sold 1,238 shares of Natera stock. The shares were sold at an average price of $102.77, for a total transaction of $127,229.26.
• On Thursday, July 25th, Michael Burkes Brophy sold 690 shares of Natera stock. The shares were sold at an average price of $105.29, for a total transaction of $72,650.10.

Natera Trading Up 0.4 %

NASDAQ NTRA opened at $119.17 on Friday. The company has a market capitalization of $14.74 billion, a PE ratio of -48.64 and a beta of 1.53. The company has a fifty day moving average of $123.37 and a 200 day moving average of $111.09. Natera, Inc. has a 1 year low of $36.90 and a 1 year high of $133.54. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.14 and a quick ratio of 4.01.

Natera (NASDAQ:NTRA) last posted its earnings results on Thursday, August 8th. The medical research company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.39. The company had revenue of $413.35 million during the quarter, compared to the consensus estimate of $343.00 million. Natera had a negative net margin of 21.47% and a negative return on equity of 36.74%. The firm’s quarterly revenue was up 58.1% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.97) earnings per share. Research analysts forecast that Natera, Inc. will post -1.96 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have issued reports on the stock. TD Cowen lifted their price target on shares of Natera from $137.00 to $145.00 and gave the stock a “buy” rating in a report on Friday, August 9th. StockNews.com lowered shares of Natera from a “hold” rating to a “sell” rating in a report on Friday. Stephens reaffirmed an “overweight” rating and issued a $125.00 price target on shares of Natera in a report on Friday, August 9th. BTIG Research lifted their price target on shares of Natera from $125.00 to $135.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Finally, UBS Group cut their price target on shares of Natera from $160.00 to $145.00 and set a “buy” rating on the stock in a report on Friday, August 9th. One equities research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Natera currently has an average rating of “Moderate Buy” and an average price target of $124.44.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. SG Americas Securities LLC raised its position in shares of Natera by 1,073.1% in the second quarter. SG Americas Securities LLC now owns 65,730 shares of the medical research company’s stock worth $7,118,000 after acquiring an additional 60,127 shares during the period. Russell Investments Group Ltd. raised its position in shares of Natera by 15.1% in the first quarter. Russell Investments Group Ltd. now owns 74,460 shares of the medical research company’s stock worth $6,810,000 after acquiring an additional 9,781 shares during the period. Natixis acquired a new position in shares of Natera in the first quarter worth about $758,000. Allspring Global Investments Holdings LLC raised its position in shares of Natera by 19.9% in the first quarter. Allspring Global Investments Holdings LLC now owns 863,406 shares of the medical research company’s stock worth $78,967,000 after acquiring an additional 143,246 shares during the period. Finally, Baader Bank Aktiengesellschaft acquired a new position in shares of Natera in the second quarter worth about $478,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.